The evidence base for an effective treatment of oral leukoplakia is limited. Although several options for treatment of oral leukoplakia are available, there is lack of consensus on the most appropriate methods of management and ways to minimize malignant transformation. It is hypothesized that high dietary intake of carotenoids may reduce human cancer. Observational studies on diet suggest that its role on cancer prevention effects is related to beta-carotene. Antioxidant nutrients are known to interact, and synergistic protective effect by carotenoids with vitamin C via an antioxidant pathway has been shown. The purpose of this study was to evaluate the utility of beta-carotene and vitamin C supplements for the treatment of oral leukoplakia among non smokers and to assess the efficacy of these chemo-preventive agents in clinical remission and preventing malignant transformation. A randomized double-blind controlled trial involving 46 Japanese subjects (25 males, 21 females, age: 66±8.9, age range: 38-80) with oral leukoplakia who had either never smoked or were ex-smokers was undertaken in 3 centers. Subjects were allocated either to the experimental arm (23 subjects; 10mg/day of beta-carotene and 500mg/day of vitamin C) or to the control arm (23 subjects; 50mg/day of vitamin C alone). The random allocation was performed centrally with stratification by blocking randomization according to presence or absence of dysplasia. Two in the experimental arm and one in the control arm did not receive allocated interventions. The supplements were continued over one year, and subjects followed up a further year. The serum levels of antioxidant micronutrients were measured. Scientific and ethical committees of the involved institutes approved the protocol for this study, and the written informed consent was obtained from all subjects prior to the allocation to the trial. Intention to treat analysis (ITT) was used for the analysis. During the intervention 5 in the experimental arm and 5 in the control arm dropped out. Among those 3 in the experimental arm and 4 in the control arm returned for follow up at close of study. Finally 40 subjects were analyzed. Based on the sample size calculation the power of the test has met 82%. The outcome of the clinical responses was analyzed by Fisher’s exact test for overall response rate (CR + PR). Cox proportional hazards model was used to estimate relative risk with 95% CI for the development of oral cancer. Among 19 in the experimental arm, 1 had complete remission (CR), 3 partial remission (PR), 14 no change (NC) and 1 progress disease (PD), and among 21 in the control arm 1 had PR, 16 NC and 4 PD. Three subjects with oral leukoplakia and +/- dysplasia in the control arm, so far have developed oral cancer at 11, 23 and 30 months periods from the onset of the intervention. The overall response rate was 21.1% in the experimental group and 4.8% in the control group (p =0.172). Relative risk adjusted for age, sex and dysplasia of oral cancer by the supplement of beta-carotene and vitamin C was 0.80 (95%CI: 0.56-1.14) (p =0.221). No untoward side effects have been noted. It is concluded that the supplemental low dose of beta-carotene and vitamin C was effective for neither clinical remission nor protection of cancer development statistically. Nevertheless the outcome suggests a benefit from their anti-oxidant effect for the management of potentially malignant disorders. Further large-scale intervention studies will be necessary with longer observation periods, and inclusion of biological and molecular assessments may provide useful intermediate endpoints for the evaluation of the future chemo-preventive studies.